Market Place
Sourcing Support
Kedrion Selected By Biotest To Distribute Yimmugo in U.S. After FDA Approval
01 Jul 2024 //
PR NEWSWIRE
Kedrion Announces Rare Disease Medicine RYPLAZIM® Now Available in US
29 Apr 2024 //
PR NEWSWIRE
Kedrion Announces An Extension Of The Distribution Agreement With Kamada
07 Dec 2023 //
PR NEWSWIRE
Kedrion Announces Support for Immune Deficiency Foundation Research Grant Program
25 Jul 2023 //
PR NEWSWIRE
Kedrion`s global portfolio expands to China to supply human Albumin
12 Jul 2023 //
PR NEWSWIRE
Kedrion strengthens its network of plasma collection centers
06 Dec 2022 //
PRNEWSWIRE
Kedrion Biopharma redeems €200m of its notes that fall due in 2022
02 May 2022 //
PRNEWSWIRE
Kedrion reports a 15% Ebitda on €660.4m of revenues in 2021
11 Apr 2022 //
PRNEWSWIRE
LFB & Kedrion sign an industrial cooperation agreement to supply immunoglobulins
31 Jan 2022 //
PRNEWSWIRE
Kedrion Biopharma to commercialize RYPLAZIM® (plasminogen, human-tvmh)
20 Oct 2021 //
PRNEWSWIRE
Kedrion Biopharma grows in N. America as it completes acquisition of Prometic
18 Oct 2021 //
PRNEWSWIRE
First Patient Treated in KIDCARES10, Kedrion`s Pediatric Immunodeficiency Study
13 Jul 2021 //
PRNEWSWIRE
First Patient Enrolled in KIDCARES10, Kedrion Biopharma Pediatric Primary
01 Apr 2021 //
PRNEWSWIRE
Kedrion Names Val Romberg as CEO
09 Oct 2020 //
PRNEWSWIRE
Kedrion Names Val Romberg As CEO
06 Oct 2020 //
PRNEWSWIRE
Kamada & Kedrion Biopharma Announce Results of First U.S. PMPediatric Trial
19 Aug 2020 //
PRNEWSWIRE
Leading Biotech Companies Kedrion Biopharma of Italy and Kamada Ltd. of Israel
29 Apr 2020 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.